Levels of Circulating MMCN-151, a Degradation Product of Mimecan, Reflect Pathological Extracellular Matrix Remodeling in Apolipoprotein E Knockout Mice | Zendy

Natasha Barascuk | Zendy; Efstathios Vassiliadis | Zendy; Q. Zheng | Zendy; Yong Wang | Zendy; W. Wang | Zendy; Lise Larsen | Zendy; Lars Melholt Rasmussen | Zendy; M.A. Karsdal | Zendy

Open Access

Levels of Circulating MMCN-151, a Degradation Product of Mimecan, Reflect Pathological Extracellular Matrix Remodeling in Apolipoprotein E Knockout Mice

Author(s) -

Natasha Barascuk,

Efstathios Vassiliadis,

Q. Zheng,

Yong Wang,

W. Wang,

Lise Larsen,

Lars Melholt Rasmussen,

M.A. Karsdal

Publication year - 2011

Publication title -

biomarker insights

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.075

H-Index - 31

ISSN - 1177-2719

DOI - 10.4137/bmi.s7777

Subject(s) - apolipoprotein e , extracellular matrix , knockout mouse , matrix metalloproteinase , medicine , apolipoprotein b , endocrinology , disease , biology , microbiology and biotechnology , receptor , cholesterol

Arterial extracellular matrix (ECM) remodeling by matrix metalloproteinases (MMPs) is one of the major hallmarks of atherosclerosis. Mimecan, also known as osteoglycin has been implicated in the integrity of the ECM. This study assessed the validity of an enzyme-linked immunosorbent assay (ELISA) developed to measure a specific MMP12-derived fragment of mimecan, MMCN-151, in apolipoprotein-E knockout (ApoE-KO) mice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research